Albert  Luderer net worth and biography

Albert Luderer Biography and Net Worth

Chairman & Interim CEO of Bionano Genomics

Dr. Albert Luderer has served the Bionano Board of Directors since November 2011 and served as Chairman of the Board of Directors since June 2024. He is currently also serving as interim President and CEO.

Albert Luderer has three decades of experience in biotechnology, with special focuses on technology, business development and commercialization.

Dr. Luderer is the former CEO and board director at personalized diagnostics company Integrated Diagnostics that was acquired by Biodesix.

Dr. Luderer previously served as president and CEO of BioTrove, a venture-backed molecular biological tools company that was acquired by Life Technologies. Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc.

Senior management positions at Dianon Systems (LabCorp), Boehringer Mannheim (Roche), and Corning round out Dr. Luderer’s experience in the industry. He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.

What is Albert Luderer's net worth?

The estimated net worth of Albert Luderer is at least $12.76 thousand as of September 4th, 2026. Dr. Luderer owns 8,000 shares of Bionano Genomics stock worth more than $12,760 as of October 1st. This net worth estimate does not reflect any other investments that Dr. Luderer may own. Learn More about Albert Luderer's net worth.

How do I contact Albert Luderer?

The corporate mailing address for Dr. Luderer and other Bionano Genomics executives is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. Bionano Genomics can also be reached via phone at (858) 888-7600 and via email at [email protected]. Learn More on Albert Luderer's contact information.

Has Albert Luderer been buying or selling shares of Bionano Genomics?

Albert Luderer has not been actively trading shares of Bionano Genomics over the course of the past ninety days. Most recently, on Friday, September 4th, Albert Luderer bought 4,000 shares of Bionano Genomics stock. The stock was acquired at an average cost of $1.21 per share, with a total value of $4,840.00. Following the completion of the transaction, the insider now directly owns 8,000 shares of the company's stock, valued at $9,680. Learn More on Albert Luderer's trading history.

Who are Bionano Genomics' active insiders?

Bionano Genomics' insider roster includes R. Holmlin (CEO), and Albert Luderer (Chairman & Interim CEO). Learn More on Bionano Genomics' active insiders.

Are insiders buying or selling shares of Bionano Genomics?

In the last year, Bionano Genomics insiders bought shares 2 times. They purchased a total of 8,000 shares worth more than $9,720.00. The most recent insider tranaction occured on September, 4th when insider Albert Luderer bought 4,000 shares worth more than $4,840.00. Insiders at Bionano Genomics own 0.7% of the company. Learn More about insider trades at Bionano Genomics.

Information on this page was last updated on 9/4/2026.

Albert Luderer Insider Trading History at Bionano Genomics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/4/2026Buy4,000$1.21$4,840.008,000View SEC Filing Icon  
8/21/2026Buy4,000$1.22$4,880.004,000View SEC Filing Icon  
See Full Table

Albert Luderer Buying and Selling Activity at Bionano Genomics

This chart shows Albert Luderer's buying and selling at Bionano Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bionano Genomics Company Overview

Bionano Genomics logo
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.55
Low: $1.54
High: $1.60

50 Day Range

MA: $1.30
Low: $1.06
High: $1.83

2 Week Range

Now: $1.55
Low: $1.00
High: $2.23

Volume

351,411 shs

Average Volume

476,527 shs

Market Capitalization

$18.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65